Optimising nAMD Management Through Longer-acting Therapies
Chairperson(s):A. Laidlaw UK
Speakers and presentations:
A. Laidlaw UK
18:00 Welcome and opening remarks
A. Laidlaw UK
18:01 Addressing the unmet need for longer-acting therapies for nAMD
N. Holekamp USA
18:09 Continuous delivery of anti–VEGF-A
A. Laidlaw UK
18:19 Summary
A. Laidlaw UK & N. HolekampUSA
18:20 – 18:40 Panel Discussion
18:40 Session Ends
